Citigroup 13F: Adds $7.1M to Agilent Technologies (A) Stake
The global financial giant added more than 53,000 shares of the laboratory technology company, growing its total position to 342,286 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Citigroup added 53,124 shares to its stake in Agilent Technologies, Inc. ($A), an 18.37% increase, according to a 13F filing with the SEC dated May 11, 2026. It reported 342,286 shares worth $45.54 million at the end of the quarter.
Since the filing, $A is up 0.6% after 1 week, up 18.1% after 1 month and up 55.7% to date (from the $111.08 close on May 11, 2026).
A
Agilent Technologies, Inc.
Key Points
- Citigroup boosted its stake in Agilent Technologies by 18.4% in the first quarter of 2026, bringing its total holdings to 342,286 shares valued at $45.5 million.
- Agilent shares traded at $133.04 on Friday, sitting roughly in the middle of their 52-week range of $108.35 to $163.75.
- A wave of analysts raised their price targets for Agilent in late 2026, with TD Cowen and Barclays setting targets as high as $196.00.
Get $A trade alerts by text
We text you when insiders, Congress or big funds trade $A. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Agilent Technologies, Inc. alert may contain errors. Disclosures
Citigroup lifted its position in Agilent Technologies, Inc. (NYSE: A) by 18.4% during the first quarter of 2026, according to its most recent 13F filing with the Securities and Exchange Commission. The financial institution added 53,124 shares of the healthcare company's stock, bringing its total ownership to 342,286 shares. Based on the filing date of May 11, 2026, the fund's total stake was valued at approximately $45.5 million. This backward-looking filing reflects Citigroup's holdings as of the end of the reporting period and may not represent its current market position.
Citigroup vs. the S&P 500
Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.
Citigroup Grows Its Agilent Position
The move by Citigroup represents a steady increase in its commitment to the laboratory equipment maker. Before this latest purchase, the fund held 289,162 shares. By growing the position by 18.4%, Citigroup is participating in a broader trend of institutional interest in the stock, though it follows a much larger entry by Vanguard, which added 14.4 million shares earlier in the year. This specific transaction shows Citigroup building its stake at a cost basis of $99.84 per share, significantly lower than recent trading prices.
Agilent Stock Performance and Valuation
Shares of Agilent Technologies traded at $133.04 on Friday. The stock has seen a fair amount of movement over the last year, ranging from a low of $108.35 to a high of $163.75. Currently, the company trades just above its 200-day moving average of $131.61, but below its 50-day moving average of $145.98. With a price-to-earnings (P/E) ratio of 31.9, the market is pricing Agilent at a premium compared to some peers, though its forward P/E of 23.97 suggests expectations of earnings growth in the coming year.
Recent Earnings Data
Agilent's financial health remains steady, reporting revenue of $7.37 billion for its most recent fiscal period. The company achieved revenue growth of 8.1% and maintained a healthy net margin of 19.53%. Its return on equity, a measure of how effectively management uses investor capital to generate profit, stands at 20.97%. Investors are looking ahead to the next earnings announcement, which is scheduled for November 25, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 3.8%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 4 percent. Operating income missed by 7 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 upgrade, 1 target raise, 5 target cuts.
-
Earnings quality
Gross margin up 3.1 points. Operating margin up 3.8 points. Positive free cash flow.
Earnings Call Summary
Agilent delivered a strong second quarter with $1.83 billion in revenue, up 6.3 percent core growth and beating guidance by 80 basis points. Earnings per share came in at $1.49, beating expectations by 7 cents and growing 14 percent year over year. Operating margin expanded 130 basis points to 26.4 percent, well ahead of guidance. The company is seeing robust momentum across its instrument business with double digit growth in LC LCMS and GC driven by replacement cycles and share gains. Diagnostics grew 11 percent led by the Omnis family and cancer offerings. Strategic pricing delivered over 200 basis points of contribution, exceeding the annual target of 100 basis points at midyear. Management credited the Ignite operating system for driving execution excellence and structural improvements.
Guidance Management raised full year revenue and earnings guidance. The company now expects $7.39 to $7.49 billion in annual revenue with core growth of 4.5 to 6.0 percent, up 30 basis points from prior guidance. Earnings per share guidance increased to $6.00 to $6.10, up 8 cents at the midpoint. For the third quarter, they forecast $1.83 to $1.85 billion in revenue with EPS of $1.48 to $1.50.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend Program
The company continues to return value to its shareholders through a regular dividend program. Agilent currently pays an annual dividend rate of $1.02 per share, which results in a dividend yield of 0.65%. The payout ratio is relatively conservative at 19.98%, suggesting the company has plenty of room to maintain or potentially grow the payment while reinvesting in its diagnostics and research business.
Analysts Set New Price Targets
Wall Street analysts have been largely optimistic about Agilent's prospects. On October 13, 2026, both TD Cowen and Morgan Stanley maintained positive ratings, with TD Cowen raising its price target to $196.00 and Morgan Stanley lifting its target to $190.00. Earlier in October, Barclays also maintained an Overweight rating and bumped its target to $195.00. Out of 21 analysts covering the stock, the consensus is a buy, with an average price target of $175.43, implying significant upside from current levels.
About Agilent Technologies
Agilent Technologies provides specialized tools and software for the life sciences, diagnostics, and applied chemical markets. The company makes the machines that laboratories use for liquid chromatography and mass spectrometry, which are essential for testing everything from environmental samples to new medicines. Headquartered in Santa Clara, California, Agilent operates through three main segments, including its CrossLab service division and its Applied Markets group.
What's Ahead for Agilent Technologies, Inc.
Investors should keep an eye on the company's next quarterly update in late November to see if Agilent can maintain its revenue growth trajectory. While the 13F filing from Citigroup shows a clear increase in confidence through early 2026, these reports are delayed by several weeks and only offer a snapshot of the past. Future filings will reveal whether Citigroup and other major funds continued to add shares as the stock price fluctuated throughout the summer and fall.
Related Filing Alerts
Source: Citigroup's 13F filing on $A (May 11, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Citigroup 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts